Literature DB >> 9801932

Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.

N Nakamura1, T Hamazaki, H Jokaji, S Minami, M Kobayashi.   

Abstract

We investigated the effect of 12 months' HMG-CoA reductase inhibitor treatment on plasma polyunsaturated fatty acid concentrations in 19 patients with hyperlipidemia. Arachidonic acid concentrations were significantly increased following treatment (from 110.1 +/- 20.4 mg/l to 129.2 +/- 31.6 mg/l, P < 0.05). The ratio of eicosapentaenoic acid to arachidonic acid was significantly decreased at the end of 12 months' treatment (from 0.702 +/- 0.370 to 0.541 +/- 0.204, P < 0.05). These results suggest that HMG-CoA reductase inhibitors may increase the synthesis of metabolites from arachidonic acid in patients with hyperlipidemia, and that the addition of fish oil is more effective for the prevention of coronary heart disease than HMG-CoA reductase inhibitors alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801932     DOI: 10.1007/s005990050043

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  12 in total

1.  Effects of statins on serum polyunsaturated fatty acids.

Authors:  Satoshi Kurisu
Journal:  Heart Vessels       Date:  2012-06-06       Impact factor: 2.037

Review 2.  Omega-3 fatty acids: their beneficial role in cardiovascular health.

Authors:  Gerry Schwalfenberg
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

Review 3.  How lipids may affect risk for suicidal behavior.

Authors:  Federico M Daray; J John Mann; M Elizabeth Sublette
Journal:  J Psychiatr Res       Date:  2018-06-12       Impact factor: 4.791

4.  Lipids and Suicide Risk.

Authors:  M Elizabeth Sublette
Journal:  Curr Top Behav Neurosci       Date:  2020

5.  The role of serum monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) in cardiovascular disease risk.

Authors:  Jasmin Kharazmi-Khorassani; Roshanak Ghafarian Zirak; Hamideh Ghazizadeh; Reza Zare-Feyzabadi; Sara Kharazmi-Khorassani; Sharzad Naji-Reihani-Garmroudi; Elham Kazemi; Habibollah Esmaily; Ali Javan-Doust; Hamed Banpour; Maryam Mohammadi-Bajgiran; Mohhamad Reza Besharatlou; Gordon A Ferns; Mohammad Hashemi; Majid Ghayour-Mobarhan
Journal:  Acta Biomed       Date:  2021-05-12

Review 6.  Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.

Authors:  Lane B Benes; Nikhil S Bassi; Michael H Davidson
Journal:  Vasc Health Risk Manag       Date:  2016-12-12

Review 7.  n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease.

Authors:  Shusuke Yagi; Daiju Fukuda; Ken-Ichi Aihara; Masashi Akaike; Michio Shimabukuro; Masataka Sata
Journal:  J Atheroscler Thromb       Date:  2017-08-24       Impact factor: 4.928

8.  Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders.

Authors:  Undurti N Das; László G Puskás
Journal:  Lipids Health Dis       Date:  2009-12-30       Impact factor: 3.876

Review 9.  Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.

Authors:  Undurti N Das
Journal:  Lipids Health Dis       Date:  2008-10-15       Impact factor: 3.876

10.  Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells.

Authors:  Noriko Ishihara; Sawako Suzuki; Shou Tanaka; Yasuhiro Watanabe; Daiji Nagayama; Atsuhito Saiki; Tomoaki Tanaka; Ichiro Tatsuno
Journal:  Mol Med Rep       Date:  2017-08-02       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.